Reviewer’s report

Title: Targeting Molecular Resistance in Castration-Resistant Prostate Cancer

Version: 3
Date: 22 July 2015

Reviewer: Bruce Montgomery

Reviewer’s report:

The authors have responded to the majority of the considerations raised. One of the points which I feel is still of significance is that they use the term "non-responders" at multiple points in the manuscript. The definition of "non-responder" should be included - this varies from study to study. Is this a patient who did not have PSA50 decline, came off of study for progression, etc.

Second, the data from the STAMPEDE study has now been presented at ASCO and supports use of docetaxel in most patients with de novo metastatic disease. In that context my previous comments about restricting the text to truly high risk/volume patients is now irrelevant. The authors should consider including referencing the STAMPEDE presentation from ASCO to further support this approach.

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests